Concepedia
Statistics
Publications
33
Citations
2.6K
H-Index
22
Active since
1991
Affiliations
Chugai Pharma (United States)(Current)
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute
The University of Texas MD Anderson Cancer Center
Massachusetts General Hospital
Nobuya Ishii is an author at Chugai Pharma (United States) specializing in medicine, tumor biology, and cell biology.
Top concepts
MedicineTumor BiologyCell BiologyOncologyPharmacologyCancer BiologyCancer ResearchRadiation OncologyTumor MicroenvironmentPathology
Publications per year
1991–2019
CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant
Hiroshi Sakamoto, Toshiyuki Tsukaguchi, Sayuri Hiroshima et al. · Cancer Cell · 2011 · 618 citations · Full text
Molecular Pharmacology, Resistant Gatekeeper Mutant, Drug Discovery +8
Indoleamine 2,3-Dioxygenase Serves as a Marker of Poor Prognosis in Gene Expression Profiles of Serous Ovarian Cancer Cells
Aikou Okamoto, Takashi Nikaido, Kazunori Ochiai et al. · Clinical Cancer Research · 2005 · 394 citations
Disruption of CRAF-Mediated MEK Activation Is Required for Effective MEK Inhibition in KRAS Mutant Tumors
Piro Lito, Anna Saborowski, Jingyin Yue et al. · Cancer Cell · 2014 · 304 citations · Full text
Effective Mek Inhibition, Kras Mutant Tumors, Signaling Pathway +9
Enhanced Inhibition of ERK Signaling by a Novel Allosteric MEK Inhibitor, CH5126766, That Suppresses Feedback Reactivation of RAF Activity
Nobuya Ishii, Naoki Harada, Eric W. Joseph et al. · Cancer Research · 2013 · 160 citations
Raf Feedback Limits, Raf Activity, Cancer Biology +17
Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine
James Nagarajah, Mina Le, Jeffrey A. Knauf et al. · Journal of Clinical Investigation · 2016 · 134 citations · Full text
Engineering, Erk Inhibition, Tumor Biology +20
1–5 of 33